Oncotarget

Research Papers:

High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma

Min Luo, Wei Sun, Cheng Wu, Linli Zhang, Dongbo Liu, Wenwen Li, Qi Mei _ and Guoqing Hu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:67651-67662. https://doi.org/10.18632/oncotarget.18798

Metrics: PDF 548 views  |   HTML 1075 views  |   ?  


Abstract

Min Luo1, Wei Sun1, Cheng Wu1, Linli Zhang1, Dongbo Liu1, Wenwen Li1, Qi Mei1 and Guoqing Hu1

1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, People’s Republic of China

Correspondence to:

Qi Mei, email: borismq@hotmail.com

Guoqing Hu, email: gqhu@tjh.tjmu.edu.cn

Keywords: nasopharyngeal carcinoma, serum marker, gamma-glutamyl transpeptidase, survival, prognosis

Received: September 20, 2016     Accepted: June 02, 2017     Published: June 28, 2017

ABSTRACT

Background: Gamma-glutamyl transpeptidase (GGT) which plays an important role in tumor initiation, invasion, drug resistance is strongly associated with poor prognosis in patients with cancers. This study was designed to estimate whether pretreatment serum GGT could predict the clinical outcome of nasopharyngeal carcinoma (NPC) patients.

Results: An optimal cutoff value was identified as 23 U/L for GGT. Univariate analysis and multivariate analysis demonstrated that elevated GGT was correlated with shorter local recurrence-free survival (LRFS) (HR, 4.163; 95% CI, 1.690-10.251; p=0.023), progression-free survival (PFS) (HR, 3.119; 95% CI, 1.955-4.976; p=0.031) and overall survival (OS) (HR, 2.811; 95% CI, 1.614-4.896; p=0.007).

Materials and Methods: We retrospectively analyzed data from 374 patients with NPC. Kaplan–Meier method was used to calculate and compare the prognosis. The Cox proportional hazards model was applied to carry out univariate and multivariate analyses.

Conclusion: Pretreatment GGT can be a novel and independent prognostic biomarker for patients with NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18798